WHO: International authorization for corona antibody testing


The Access to Technology Pool and the Pharmaceutical Patent Pool of the World Health Organization has approved the licensing agreement.

To produce and distribute a coronavirus antibody test kit developed by the Spanish National Research Council.


In a statement issued by the World Health Organization (WHO), it was announced that for the first time an international license had been granted for antibody testing for coronavirus.

He identified the Technology Access Pool (C-TAP) and the Pharmaceutical Patents Pool (MPP) of the World Health Organization.

The test kit developed by the Spanish National Research Council (CSIC) can effectively measure the rate of antibodies in the human body, and the possibility of detecting infection with the virus or the Corona vaccine was announced.

It has been noted that this antibody test unlike other tests can be applied in simple laboratories.


With the widespread use of testing, low-income countries can provide concrete data on the number of people with antibodies to corona.

It was shared that test results can be retained and read against the color chart with the naked eye without any device and that the test accuracy rate is higher in microplate readers.

It was also emphasized that middle and low-income countries would not be charged patent fees for the production and distribution of the antibody test.

C-TAP’s founding country, Carlos Alvarado Quesada, president of Costa Rica, said in a statement regarding the licensing agreement.


“This license is a testament to what we can achieve when people are put at the center of our global and multilateral efforts.”

Kisada expressed his gratitude to the Spanish government for this development, which concerns global public health.

Tedros Ghebreyesus, Director-General of the World Health Organization, stated that the antibody test kit produced by CSIC has been registered as an important example of solidarity in the fight against Corona.

Ghebreyesus stressed that countries and companies producing vaccines should take the responsible behavior of CSIC as an example.


“We need such open and transparent licenses in order to effectively combat the epidemic.”